Reply by Wolfe, Frederick et al.
The study included patients (n  1,002) with local and
widespread pain from 55 centers. Using the 1990 Ameri-
can College of Rheumatology (ACR) FM criteria, including
the assessment of tender points, the patients were diag-
nosed as having FM (Wolfe F, Smythe HA, Yunus MB,
Bennett RM, Bombardier C, Goldenberg DL, et al. The
American College of Rheumatology 1990 criteria for the
classification of fibromyalgia: report of the Multicenter
Criteria Committee. Arthritis Rheum 1990;33:160–72).
Widespread pain was assessed by body pain drawing, and
extensive questionnaires were applied. After a series of
analyses, Wolfe et al concluded that a widespread pain
index was the best predictor of FM. When this index was
excluded from the analysis, key predictors of FM were
nonrefreshing sleep, fatigue, cognitive difficulties, and a
host of somatic symptoms. These 4 variables were then
combined into a symptom severity scale, which ranged
from 0–12. This symptom severity scale highly correlated
with both the tender point count and the widespread pain
index. The combination of the symptom severity scale and
the widespread pain index identified 80.9% of the FM
cases previously diagnosed by the 1990 ACR criteria.
Furthermore, the symptom severity scale was useful for
identifying previously diagnosed FM in patients who no
longer satisfied ACR criteria. In phase 2 of their study,
Wolfe et al collected the widespread pain index and symp-
tom severity scale scores and reported that they performed
well for diagnosing FM.
Wolfe and colleagues promote new diagnostic criteria
that are almost as good (80% correct classification) as the
previous criteria. The irony of this approach is that these
1990 ACR criteria had been previously disparaged by the
same authors. Therefore, it is hard to consider this an
advance of the clinical science.
Wolfe and colleagues are to be commended for this
attempt at simplifying the diagnostic criteria for FM for
general practitioners and specialists alike. Most of us will
agree that the 1990 ACR criteria for FM lacked important
illness features such as fatigue, morning stiffness, dis-
turbed sleep, affective distress, etc. Wolfe et al remedied
this omission by including several of these features, such
as nonrestorative sleep, fatigue, and dyscognition, into the
new criteria. Nevertheless, there is a glaring omission of
well-known mechanistic FM features, such as hyperalge-
sia, central sensitization, or dysfunctional pain modula-
tion.
We also doubt that the new criteria can provide more
precision (specifically for characterization of FM sub-
groups) mostly because of the vagueness of the proposed
criteria (fatigue, dyscognition, and nonrestorative sleep).
Also, the somatic symptom list is extremely broad (41
somatic symptoms), and the symptoms are ordered by
neither relevance nor predictive value, etc., supposedly
contributing equally to FM. In conclusion, whether or not
these new criteria are easy to apply by practicing physi-
cians will require empirical testing. Unfortunately, the
new criteria are imprecise, ill-defined, lack mechanistic
features, and are completely symptom focused. They also
subscribe to the same circular logic as the 1990 ACR cri-
teria. Would it be better to teach physicians how to test
tender points and therefore keep the old criteria? New
criteria for FM are needed, but we doubt that Wolfe and
colleagues have made the necessary quantum leap to ad-
vance this important issue.
Dr. Staud has received consultant fees, speaking fees, and/or
honoraria (less than $10,000 each) from Forest Laboratories and
Jazz Pharmaceuticals.
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We thank Drs. Thompson, Vanderschueren, Staud, and
colleagues for their comments on the new diagnostic cri-
teria for fibromyalgia. We note that Dr. Thompson finds the
ACR 2010 criteria problematic because she feels there can
be confusion between fibromyalgia and MPS, when the
latter affects several body regions. It seems unavoidable
that disorders that affect muscle might cause confusion
with fibromyalgia. However, as noted by Dr. Thompson, in
the case of MPS there are criteria that exist to define MPS.
So ordinarily the 2 disorders should be distinguishable
except, of course, if they are both present simultaneously.
We hope that clinicians who use diagnoses like fibromy-
algia and MPS would apply current diagnostic methods at
the time of diagnosis.
We are grateful to Dr. Steven Vanderschueren and col-
leagues for raising very important questions about our
study and criteria. To paraphrase their first point, they
indicate that pain is not simple and that criteria that aban-
don the physical examination may result in poor medical
care. We address this point in our criteria article when we
state, “Even though the new criteria do not include a
physical examination criterion, all of the patients being
diagnosed should have a physical examination, which
may include examination of tender point sites. . .It is im-
portant for physicians to perform an appropriate clinical
assessment to exclude other diagnoses, and/or to identify
potential coexisting rheumatic diseases that may require
treatment themselves.” For clinical assessment, we would
include some measure of tenderness or pain threshold, but
not necessarily a formal tender point count.
Where Vanderschueren et al indicate that “the article
clearly shows that the tender point count is the most
reliable feature to differentiate fibromyalgia and nonfibro-
myalgia patients,” we would respond that it is true, of
course, because we used the 1990 criteria (1) as a gold
standard. That does not mean that tender points are better
than other methods; it merely means that they represented
the gold standard test for the criteria development. There
are substantial issues with the reliability of the tender
point examination.
In their second point, Vanderschueren et al state, “The
new diagnostic criteria, as opposed to the ACR 1990 clas-
sification criteria, implicitly state that fibromyalgia should
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be a diagnosis of exclusion, without detailing what painful
disorders should be ruled out or what tests should be
performed for that reason. In contrast, the 1990 classifica-
tion criteria made no exclusions for the presence of con-
comitant radiographic or laboratory abnormalities and
abandoned the distinction between primary fibromyalgia
and secondary-concomitant fibromyalgia.” We think that
Vanderschueren and colleagues have misinterpreted our
discussion of exclusionary diagnoses. As a study exclu-
sion criterion, we wrote, “The patient does not have a
disorder that would otherwise explain the pain,” and we
indicated that “implicit in the 1990 ACR classification
criteria was the requirement that clinical examination and
clinical judgment had excluded other causes of chronic
widespread pain, and such an exclusion is also implicit in
the proposed diagnostic criteria.” Most of us, for example,
would not exclude other rheumatic diseases.
Vanderschueren and colleagues make their third point
by saying, “The control group consisted of patients with
noninflammatory painful rheumatic disorders. The pro-
portion of control persons with a fibromyalgia diagnosis
increased 4-fold (from 2.0% using the 1990 criteria to
9.1% using the new criteria).” We believe this is not cor-
rect. The false-positive rate in the 1990 criteria was 18.9%
(1). In this third point Vanderschueren and colleagues also
wonder whether abandoning the tender point count will
open “Pandora’s Box.” If we understand Vanderschueren
et al correctly, they are worried about misdiagnosis, i.e.,
calling other conditions fibromyalgia that are really not
fibromyalgia. This question really goes to the heart of what
fibromyalgia means in the presence of other illnesses. Per-
haps some of the patients Vanderschueren and colleagues
are worried about should be classified as fibromyalgia
patients. We would also point out the strong correlation
between the WPI and the tender point count, as shown in
Table 3 of the 2010 criteria, and the similar association of
both variables with the symptoms we are concerned with.
Based on the data from our study, we think it is very
unlikely that the new criteria will misclassify many pa-
tients.
The fourth point made by Vanderschueren and col-
leagues is that fibromyalgia patients in this study were
older (mean age 54.6 years), suggesting that many had the
label for quite some time. In a recent population study, the
mean age of fibromyalgia patients was 48.9 years (2). If age
is a random variable, we expect age to vary from sample to
sample. Even so, age made no difference in the results of
our study. In response to the point made by Vanders-
chueren and colleagues that “a fair share of subjects ended
up in the ‘prior fibromyalgia’ category,” we would have to
observe that “prior” doesn’t reflect age, but rather reflects
diagnostic change.
In their fifth point, Vanderschueren et al are concerned
that “many patients (36.4%) entering the present study as
fibromyalgia patients were labeled as such not based on
the ACR classification criteria, but on the personal judg-
ment of the study physician.” The choice to allow patients
who were diagnosed without ACR criteria was deliberate.
In attempting to slightly change the case definition of
fibromyalgia, we wanted to know how rheumatology phy-
sicians were defining the disorder. That is, what is the
current actual case definition in practice? It has been
known from the time of the 1990 criteria that experts might
make a diagnosis even when criteria were not satisfied.
Vanderschueren et al confuse patients used to make a
more valid case definition and the actual criteria that were
evaluated against the 1990 criteria. Fibromyalgia can be a
difficult problem. We believe that we have scientifically
addressed the case definition and found the best criteria
for the condition.
If we understand what seems to be Dr. Staud’s main
point correctly, that we omitted “well-known mechanistic
FM features, such as hyperalgesia, central sensitization, or
dysfunctional pain modulation” from the criteria, we
would reply that central sensitization and dysfunctional
pain modulation are not features that can be reasonably
assessed in the clinic, and that the widespread pain index
provides a measure of hyperalgesia that, as the data show,
is equivalent to the tender point count.
With respect to the symptom list, Dr. Staud is mistaken
about not reporting the predictive value of the symptoms.
We do report the importance of the symptoms in Figure 2,
and in importance order. Dr. Staud may assume that vari-
ables not in the figure do not contribute to classification.
Dr. Staud writes that we “promote new diagnostic crite-
ria that are almost as good (80% correct classification) as
the previous criteria.” This is not correct. Table 5 shows
that among patients satisfying ACR 1990 criteria, 88.1%
satisfied 2010 criteria in phase 1 and 95.2% in phase 2. In
addition, when all patients are considered, not just ACR
1990 positive patients, we wrote in the text, “It should be
remembered that physician diagnosis only correctly clas-
sified 84.1% of cases, while the proposed diagnostic cri-
teria, even with shift of definition, identified 82.6% of
patients correctly.”
Dr. Staud writes, “They [the criteria] also subscribe to
the same circular logic as the 1990 ACR criteria.” He
should reread the paragraph in the discussion beginning
with, “Readers might wonder: why is it so difficult to make
new fibromyalgia criteria? The central problem in fibromy-
algia criteria is the absence of a gold standard or case
definition.” Later in the paragraph we point out that, “In
the current study, we derived an empirical case definition
from the variable importance analyses.”
If Dr. Staud is not satisfied with the new criteria, he may
continue to use the old ones (the ones he criticized for
being circular). But one advantage to the new criteria that
warrants mentioning is that the change in the case defini-
tion demands that the patient’s symptoms be paid atten-
tion to. Who would want less?
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